Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24245771 | 1.00 | ALOX15 (0.39) | ALOX15ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL8912423 | 1.00 | ALOX15 (0.39) | ALOX15ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL3503734 | 1.00 | ALOX15 (0.39) | ALOX15ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL18138232 | 1.00 | ALOX15 (0.39) | ALOX15ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL24245773 | 1.00 | ALOX15 (0.39) | ALOX15ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL8912413 | 1.00 | ALOX15 (0.39) | ALOX15ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL14081522 | 0.71 | ALOX15 (0.47) | ALOX15ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL15291459 | 0.71 | TSHR (0.37) | TSHR | |
| SCHEMBL15314178 | 0.71 | TSHR (0.37) | TSHR | |
| SCHEMBL24722700 | 0.70 | ALOX15 (0.39) | ALOX15ALDH1A1LMNATHRBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219918-A1 | (3aS,4aR,5S,7aS,9R,9aR)-2,2,5,8,8,9a-hexamethyloctahydro-4H-4a,9-methanoazuleno[5,6-d][1,3]dioxole | GIVAUDAN SA (CH) | 2023-07-13 | — | — | US | disclosed |
| US-20230219918-A1 | (3aS,4aR,5S,7aS,9R,9aR)-2,2,5,8,8,9a-hexamethyloctahydro-4H-4a,9-methanoazuleno[5,6-d][1,3]dioxole | GIVAUDAN SA (CH) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219918-A1 | (3aS,4aR,5S,7aS,9R,9aR)-2,2,5,8,8,9a-hexamethyloctahydro-4H-4a,9-methanoazuleno[5,6-d][1,3]dioxole | DHRS9, MSMO1, CYP4X1 | ALOX15 763/4885ALDH1A1 669/4885LMNA 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.